PharmaZell acquires GEA Pharmaceuticals from Sandoz
PharmaZell, located near Munich in Germany has acquired from Sandoz a controlling stake in GEA Pharmaceuticals based in Copenhagen, Denmark.
PharmaZell, located near Munich in Germany has acquired from Sandoz a controlling stake in GEA Pharmaceuticals based in Copenhagen, Denmark.
PharmaZell is a material and service provider to the pharmaceutical industry with API production sites in Germany and India.
The acquisition is an important step to secure the continued growth of the company and will enable it to provide the entire range of contract services required in drug development from APIs to Regulatory Affairs.
GEA Pharmaceuticals focuses on the development of solid finished dosage forms. It offers a full range of pharma development services from analytics to the filing of pharmaceutical registration dossiers. The company also manufactures APIs and intermediates under GMP and high environmental standards.
GEA's broad capabilities in solid finished dosage form development and the experience in narcotic pharmaceuticals complement the portfolio of services and products offered by Pharmazell. It also adds needed production and development capacities, particularly for niche products. The 80 highly skilled employees of GEA will be retained.
A minority stake in GEA is held by the BDD group, a contract research organisation engaged in non-clinical and clinical development.